ANTIVIRAL ACTIVITY;
ANTIVIRAL RESISTANCE;
ARTICLE;
BLOOD LEVEL;
COMBINATION CHEMOTHERAPY;
DIRECT ANTIVIRAL ACTIVITY;
DRUG APPROVAL;
DRUG COST;
DRUG MONITORING;
DRUG RESPONSE;
DRUG TREATMENT FAILURE;
GENOTYPE;
HEALTH CARE QUALITY;
HEPATITIS C;
HEPATITIS C VIRUS;
HUMAN;
NONHUMAN;
PRIORITY JOURNAL;
REAL TIME POLYMERASE CHAIN REACTION;
TREATMENT DURATION;
VIRAL CLEARANCE;
VIRUS DETECTION;
VIRUS REPLICATION;
ADVERSE EFFECTS;
BLOOD;
DRUG COMBINATION;
ECONOMICS;
HEPACIVIRUS;
HEPATITIS C, CHRONIC;
ISOLATION AND PURIFICATION;
PROCEDURES;
ANTIVIRAL AGENTS;
DRUG MONITORING;
DRUG THERAPY, COMBINATION;
HEPACIVIRUS;
HEPATITIS C, CHRONIC;
HUMANS;
RNA, VIRAL;
World Health Organization HCV updated on April 2013. Available at: (last accessed 20 May 2014).
World Health Organization HCV updated on April 2013. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/ (last accessed 20 May 2014).
2
84879795584
Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin
Manns MP, Pockros PJ, Norkrans G et al. Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin. J Viral Hepatol 2013; 20: 524-529.
European Association for the Study of the Liver Recommendations on Treatment of Hepatitis C. Available at: (last accessed 20 May 2014).
European Association for the Study of the Liver Recommendations on Treatment of Hepatitis C. 2014. Available at: http://www.easl.eu/_newsroom/latest-news/easl-recommendations-on-treatment-of-hepatitis-c-2014 (last accessed 20 May 2014).
(2014)
4
84916929524
American Association for the Study of the Liver Diseases Recommendations for Testing, Managing, and Treating Hepatitis C. Available at: (last accessed 20 May 2014).
American Association for the Study of the Liver Diseases Recommendations for Testing, Managing, and Treating Hepatitis C. Available at: http://www.hcvguidelines.org/ (last accessed 20 May 2014).
5
84898990930
New hepatitis C therapies: the toolbox, strategies, and challenges
Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014; 146: 1176-1192.
Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
Halfon P, Sarrazin C. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? Liver Int 2012; 32(suppl 1): 79-87.
In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir
Tong X, Le Pogam S, Li L et al. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis 2014; 209: 668-675.
